ras activity and cyclin D1 expression: An essential mechanism of mouse skin tumor development

Molecular Carcinogenesis

Volumn 24, Issue 1, 1999, Pages 1-6

  Rodriguez Puebla, Marcelo L ^a   Robles, Ana I ^a,b   Conti, Claudio J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cell cycle; Cyclin D1; Ras; Skin tumors

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; RETINOBLASTOMA PROTEIN;

CELL CYCLE; NONHUMAN; ONCOGENE RAS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SKIN CARCINOGENESIS; SKIN TUMOR; TUMOR GROWTH;

ANIMALS; CELL CYCLE; CYCLIN D1; CYCLIN-DEPENDENT KINASES; GENES, RAS; HUMANS; MICE; POINT MUTATION; RAS PROTEINS; RETINOBLASTOMA PROTEIN; SKIN NEOPLASMS;

EID: 0032909693     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199901)24:1<1::AID-MC1>3.0.CO;2-E     Document Type: Review

References (61)

1. Barbacid M. ras genes. Annu Rev Biochem 1987;56:779-827.
2. Cahill MA. Signalling pathways: Lack of all cascades. Curr Biol 1996;6:16-19.
3. Boguski M, McCormick F. Proteins regulating ras and its relatives. Nature 1993;366:648-650.
4. Katz ME, McCormick F. Signal transduction from multiple Ras effectors. Curr Opin Genet 1997;7:75-79.
5. Marshall CJ. Specificity of receptor tyrosine kinase signalling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-185.
6. Mangues R, Pellicer A. ras activation in experimental carcinogenesis. Semin Cancer Biol 199;3:229-239.
7. Pardee AB. G1 events and regulation of cell proliferation. Science 1989;246:603-608.
8. Hunter T, Pines J. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 1994;79:573-582.
9. Sherr CJ. G1 phase progression: Cyclin on cue. Cell 1994;79: 551-555.
10. Sherr CJ, Mammalian G1 cyclins. Cell 1993;73:1059-1065.
11. Koff A, Giordano A, Desai D, et al. Formation and activation of a cyclin E-cdk2 complex during G1 phase of the human cell cycle. Science 1992;257:1689-1693.
12. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cydin-dependent kinases. Genes Dev 1995;9:1149-1163.
13. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330.
14. Nevins J, Chellappan S, Mudryj M, et al. E2F transcription factor is a target for the RB protein and the cyclin A protein. Cold Spring Harb Symp Quant Biol 199;56:157-162.
15. Nevins JR. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992;258:424-429.
16. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677.
17. Jiang W, Zhang Y-J, Khan SM, et al. Altered expression of the cyclin D1 and retinoblastome genes in human esophageal cancer. Proc Natl Acad Sci USA 1992;90:9026-9030.
18. Bartkova J, Lukas J, Strauss M, Bartek J. The PRAD1/cyclin D1 oncogene product accumulate aberrantly in a subset of colorectal carcinomas. Int J Cancer 1994;58:568-573.
19. Schauer IE, Siriwardana S, Langan TA, Sclafani RA. Cyclin D1 overexpression vs. retinoblasoma inactivation: Implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci USA 1994;91:7828-7831.
20. Aagaard L, Lukas J, Bartkova J, et al. Aberrations of p16Ink4 and retinoblastoma tumor-suppressor genes occur in distinct subsets of human cancer cell lines, Int J Cancer 1995;61:115-120.
21. Otterson GA, Kratze RA, Coxon A, Kim YW, Kaye FJ. Absence of p16Ink4 protein is restricted to a subset of lung cancer cell lines that retains wildtype RB. Oncogene 1994;9:3375-3378.
22. Shapiro GI, Edwards CD, Kobzik L, et al. Reciprocal Rb inactivation and p16Ink4 expression in primary lung cancers and cell lines. Cancer Res 1995;55:505-509.
23. Lukas J, Aagaard L, Strauss M, Bartek J. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res 1995;55:4818-4823.
24. Arber N, Sutler T, Miyake M, et al. Increased expression of cyclin D1 and the RB tumor suppressor gene in c-K-ras transformed rat enterocytes. Oncogene 1996;12:1903-1908.
25. Filmus J, Robles AI, Shi W, et al. Induction of cyclin D1 overexpression by activated ras. Oncogene 1994;9:3627-3633.
26. Liu JJ, Chao JR, Jiang MC, et al. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH3T3 cells. Mol Cell Biol 1995;15:3654-3663.
27. Albanese C, Johnson J, Watanabe G, et al. Transforming p21 ras mutants and c-Ets-2 activated the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995;270:23589-23597.
28. Mechta F, Lalleman D, Pfarr CM, Yaniv M. Transformation by ras modifies AP1 composition and activity. Oncogene 1997;14: 837-847.
29. Weber JD, Hu W, Jefcoat SC, Raben DM, Baldassare JJ. Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27Kip1. J Biol Chem 1997;272:32966-32971.
30. Aktas H, Cai H, Cooper G. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the cdk inhibitor p27Kip1. Mol Cell Biol 1997;17:3850-3857.
31. Takuwa N, Takuwa Y. Ras activity in G1 phase required for p27 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH3T3 fibroblasts. Mol Cell Biol 1997;17:5348-5358.
32. Serrano M, Gomes-Lahoz E, DePinho RA, Beach D, Bar-Sagi D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 1995;267:249-252.
33. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
34. Pepper DS, Upton TM, Ladha MH, et al. Ras signalling linked to cell-cycle machinery by the retinoblastome protein. Nature 1997;386:177-181.
35. Kivinen L, Tiihonen, E, Haapajarvi T, Laiho M. p21ras-mediated decrease of the retinoblastoma protein in fibroblasts occurs through growth factor-dependent mechanism. Cell Growth Differ 1996;7:1705-1712.
36. Fan J, Bertino JR. K-ras modulates the cell cycle via both positive and negative regulatory pathways. Oncogene 1997;14:2595-2606.
37. Kang J-S, Krauss RS. Ras induces anchorage-independent growth by subverting multiple adhesion-regulated cell cycle events. Mol Cell Biol 1996;16:3370-3380.
38. Yang J-J, Kang J-S, Krauss RS. Ras signals to the cell cycle machinery via multiple pathways to induce anchorage-independent growth. Mol Cell Biol 1998;18:2586-2595.
39. Slaga TJ. Cellular and molecular mechanisms involved in multistage skin carcinogenesis. In: Conti CJ, Slaga TJ, Klein-Szanto AJ, editors. Carcinogenesis. A comprehensive survey. New York: Raven Press. 1989; p1-18.
40. Balmain A, Pragnell I. Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature 1983;303:72-74.
41. Bizub D, Wood A, Skalka A. Mutagenesisof the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons. Proc Natl Acad Sci USA 1986;83:6048-6052.
42. Roop D, Lowy D, Tambourin P, et al. An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. Nature 1986;323:822-824.
43. Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986;322:78-80.
44. Burns FJ, Vanderlaan M, Snyder E, Albert RE. A comprehensive survey. In: Slaga TJ, Sivak A, Boutwell RR, editors. Carcinogenesis. New York: Raven Press; 1978. p. 91-96.
45. Greenhalgh D, Quintanilla M, Orengo C, et al. Cooperation between v-fos and v-Ha-ras induces autonomous papillomas in transgenic epidermis but not malignant conversion. Cancer Res 1993;53:5071-5075.
46. Greenhalgh D, Rothnagel J, Quintanilla M, et al. Induction of epidermal hyperplasia, hyperkeratosis, and papillomas in transgenic mice by a targeted v-Ha-ras oncogene. Mol Carcinog 1993;7:99-110.
47. Leder A, Kuo A, Cardiff R, Sinn E, Leder P. v.-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: Effects of phorbol esters and retinoic acid. Proc Natl Acad Sci USA 1990;87:9178-9182.
48. Spalding J, Momma J, Elwell M, Tennant R. Chemically induced skin carcinogenesis in a transgenic mouse line (TG.AC) carrying a v-Ha-ras gene. Carcinogenesis 1993;14:1335-1341.
49. Bianchi AB, Fischer SM, Robles AI, Rinchik EM, Conti CJ. Overexpression of cyclin D1 in mouse skin carcinogenesis. Oncogene 1993;8:1127-1133.
50. Robles AI, Conti CJ. Early overexpression of cyclin D1 protein in mouse skin carcinogenesis. Carcinogenesis 1995;16:781-786.
51. Rodriguez-Puebla ML, LaCava M, Gimenez-Conti IB, Johnson DG, Conti CJ. Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin. Oncogene 1998;17:2251-2258.
52. Rodriguez-Puebla ML, Robles AI, Johnson DG, LaCava M, Conti CJ. Synchronized proliferation induced by 12-O-tetradecanoylphorbol-13-acetate treatment of mouse skin: An in vivo model for cell cycle regulation. Cell Growth Differ 1998;9:31-39.
53. Robles AI, Rodriguez-Puebla ML, Glick AB, et al. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 1998;12:2469-2474.
54. Sicinski P, Donaher JL, Parker SB, et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995;82:621-630.
55. Gangarosa LM, Sizemore N, Graves-Deal R, et al. A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of ras intestinal epithelial cells. J Biol Chem 1997;272:18926-18931.
56. Oldham SM, Clark GJ, Gangarosa LM, Coffey RJ, Der CJ. Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells. Proc Natl Acad Sci USA 1996;93:6924-6928.
57. Dlugosz AA, Hansen L, Cheng C, et al. Targeted disruption of the epidermal growth factor receptor impairs growth of squamous papillomas expressing the v-Ha-ras oncogene but does not block in vitro keratinocyte responses to oncogenic ras. Cancer Res 1997;57:3180-3188.
58. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 1995;9:2364-2372.
59. Robles AI, Larcher F, Whalin RB, et al. Expression of cyclin D1 in epithelial tissues of transgenic mice results in epidermal hyperproliferation and severe thymic hyperplasia. Proc Natl Acad Sci USA 1996;93:7634-7638.
60. Pierce AM, Fischer S, Conti CJ, Johnson DG. Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development. Oncogene 1998;16:1267-1276.
61. Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, et al. Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci USA 1998;95:8858-8863.